APLLTD · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 32/100 — Quality 51 · Valuation 35 · Growth 14 · Momentum 13
| Share price | ₹842.65 |
| Market cap | ₹14,013 Cr |
| P/E ratio | 22.2 |
| P/B ratio | 2.6 |
| ROE | 13.2% |
| ROCE | 14.7% |
| Dividend yield | 1.55% |
| Book value | ₹270.70 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹7,345 Cr | ₹671 Cr | 15.0% |
| 2025 | ₹6,672 Cr | ₹582 Cr | 15.0% |
| 2024 | ₹6,229 Cr | ₹616 Cr | 15.0% |
| 2023 | ₹5,653 Cr | ₹342 Cr | 12.0% |
| 2022 | ₹5,306 Cr | ₹521 Cr | 16.0% |
Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It a